Breast cancer Cancer Breast
Conditions
Interventions
Patients will be randomised to one of the following:
1. CMF Regimen: Chemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil), a maximum of six cycles. Folinic acid to be given every 6
Sponsors
Cancer Research UK (CRUK) (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically proven breast cancer, metastatic or incurable locally recurrent disease 2. No other malignancy except adequately treated in situ carcinoma of cervix or non melanomatous skin cancer 3. Previous adjuvant chemotherapy or neo-adjuvant chemotherapy is acceptable, unless the disease free interval is <2 years following adjuvant CMF chemotherapy 4. Previous chemotherapy for metastatic disease is acceptable 5. Patients must be willing to complete quality of life questionnaire and be interviewed by a senior nurse 6. Normal liver function 7. Patients must be considered fit enough to receive either standard CMF or MMM chemotherapy
Exclusion criteria
Exclusion criteria: 1. Patients are not eligible if they are eligible for a first line phase II study. Patients may become eligible at the time of progression 2. Patient are not eligible if they present with immediately life threatening disease for whom the physician considers an anthracycline based combination preferable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed